Bernie Sanders Outraged Once-Free Drug Now Costs $375,000

Sanders wants to know “how many patients will suffer or die” because of the price hike.

Sen. Bernie Sanders (I-Vt.) is demanding to know why a pharmaceutical company has slapped a $375,000 list price on a drug that patients used to get for free.

Sanders accused Patrick McEnany, president and CEO of Catalyst Pharmaceuticals Inc., of “a blatant fleecing of American taxpayers” and “an immoral exploitation of patients who need this medication” in a scathing letter Monday.

The drug, known as Firdapse, treats a rare autoimmune disease called Lambert-Eaton myasthenic syndrome, which fatigues and weakens muscles by causing the body to attack its own tissues.

The drug had been available at no cost for two decades under the name 3,4-DAP from Jacobus Pharmaceutical as part of the Food and Drug Administration’s compassionate use program. The drug, though unapproved specifically for Lambert-Eaton myasthenic syndrome, often was prescribed by doctors for the condition.

Catalyst in November won expedited FDA approval to sell Fidapse as the first treatment for Lambert-Eaton myasthenic syndrome. A month later, the company announced the list price for a year’s treatment: $375,000.

Now, Sanders is asking “how many patients will suffer or die” because they can’t afford the medication.

“This is no longer a speculative issue of pricing ― this is a real issue, and it is an access issue,” the lawmaker wrote. “By setting such a high price and forcing production and distribution of the older, inexpensive version to cease, you are threatening access that patients had to a cheap version of this product, and handing a completely unwarranted bill to American taxpayers.”

Sanders noted that Catalyst has reportedly said many patients will be charged only around $10 a month for the medication. Nevertheless, he asked the company to provide the average price, and whether patients are paying high deductibles for the medicine before their insurance coverage kicks in.

Catalyst told CNN in a statement that it plans to respond to the letter soon.